iBio

iBio EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of iBio (IBIO) as of Nov 17, 2026 is -2.06. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -3.90 — a change of -47.06% (higher).

EV/EBIT

-2.06

YoY

-47.06%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of iBio is 2026 -2.06 . EV/EBIT (Enterprise Value to EBIT) of iBio was 2025 -3.90 . It decreases by -47.06% higher compared to the previous year.

The iBio EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-4.60 USD
Jan 1, 2020
-5.18 USD
Jan 1, 2021
-2.33 USD
Jan 1, 2022
-2.44 USD
Jan 1, 2023
-2.47 USD
Jan 1, 2024
-4.36 USD
Jan 1, 2025
-3.90 USD
Jan 1, 2026
-2.06 USD
The iBio EV/EBIT history
YEAREV/EBITYoY
-2.06-47.06%
-3.90-10.58%
-4.36+76.21%
-2.47+1.32%
-2.44+4.76%
-2.33-55.02%
-5.18+12.71%
-4.60-9.92%
-5.11+0.01%
-5.10-30.38%
-7.33-32.62%
-10.88-42.39%
-18.89+356.30%
-4.14+2.73%
-4.03+13.84%
-3.54-86.91%
-27.05+61.20%
-16.78+2,297.14%
-0.70—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iBio Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides iBio's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates iBio's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots iBio's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if iBio grows earnings faster than its peers.

iBio Stock analysis

What does iBio do? iBio, Inc. generates revenue through the commercialization of its plant-based protein expression technologies, which are used for developing vaccines and therapeutic proteins. The company's iBioLaunch technology and iBioModulator platform enable the production of biologics in hydroponically grown green plants, targeting fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of plasma-derived products. Clients and collaborators purchase product development and manufacturing services, leveraging iBio's transformative platform for biologics production. The firm focuses on both its own product candidates and providing services to external partners in the biopharmaceutical sector. iBio's business model centers on offering its proprietary technologies as a service to clients, with a focus on developing and manufacturing biologics through plant-based systems. The company's technologies are applicable across multiple therapeutic areas, including fibrotic disease treatments, vaccine development, and enzyme replacement therapies. By providing these services, iBio supports clients in creating advanced biopharmaceutical products without the need for traditional manufacturing infrastructure. The company's revenue streams include the sale of its iBioLaunch and iBioModulator platforms, as well as product development and manufacturing services for biopharmaceutical clients. These services are tailored to meet the needs of partners seeking efficient, scalable production methods for biologics. iBio's focus on plant-based production differentiates it in the market, appealing to clients looking for innovative approaches to biologic manufacturing. iBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iBio stock

EV/EBIT (Enterprise Value to EBIT) of iBio is -2.06 in 2026.

EV/EBIT (Enterprise Value to EBIT) of iBio changed from -3.90 to -2.06, representing a -47.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) iBio since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s iBio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — iBio

All Key Metrics — iBio